Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Invested Capital (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Invested Capital for 6 consecutive years, with $956.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 6.45% to $956.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $956.8 million, a 6.45% decrease, with the full-year FY2025 number at $956.8 million, down 6.45% from a year prior.
  • Invested Capital was $956.8 million for Q4 2025 at Janux Therapeutics, down from $976.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.0 billion in Q4 2024 to a low of -$16.8 million in Q1 2021.
  • A 5-year average of $534.8 million and a median of $371.5 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 3358.49% in 2021, then fell 12.9% in 2023.
  • Janux Therapeutics' Invested Capital stood at $366.3 million in 2021, then dropped by 12.44% to $320.7 million in 2022, then rose by 7.36% to $344.3 million in 2023, then soared by 197.02% to $1.0 billion in 2024, then dropped by 6.45% to $956.8 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Invested Capital are $956.8 million (Q4 2025), $976.6 million (Q3 2025), and $990.5 million (Q2 2025).